grant

Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM

Organization UNIVERSITY OF CALIFORNIA AT DAVISLocation DAVIS, UNITED STATESPosted 12 Sept 2021Deadline 31 Jul 2026
NIHUS FederalResearch GrantFY2025AccelerationAddressAdult-Onset Diabetes MellitusAffectBody WeightCaliforniaCaringChronicClinicalCluster randomization trialCluster randomized trialCommunitiesComplicationCost SharingDataDecision MakingDiabetes MellitusDiabetes preventionDiagnosisEarly treatmentElectronic Health RecordEnrollmentFaceFearFosteringFrightFutureGestationGestational DiabetesGestational Diabetes MellitusGlycohemoglobin AGlycosylated hemoglobin AGoalsGuidelinesHb A1Hb A1a+bHb A1cHbA1HbA1cHealthHealth CareHealth Care ProfessionalHealth ProfessionalHealth ServicesHealth systemHemoglobin A(1)HourInfrastructureInterventionKetosis-Resistant Diabetes MellitusLife StyleLifestyleLinkMaturity-Onset Diabetes MellitusMediatorMedicalMethodsMinorityModelingMotivationNIDDMNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusOGTTOral Glucose Tolerance TestOutcomePathway interactionsPatient Outcomes AssessmentsPatient Reported MeasuresPatient Reported OutcomesPatientsPerinatal CarePhasePopulationPostpartum PeriodPregnancyPregnancy ComplicationsPregnancy-Induced DiabetesPrenatal carePreventative carePreventionPreventivePreventive careProblem SolvingProviderRandomization trialRandomizedRecommendationReportingRiskSamplingScreening ResultSecureSelf CareSelf DirectionSelf EfficacyServicesSlow-Onset Diabetes MellitusStable Diabetes MellitusSurvey InstrumentSurveysT2 DMT2DT2DMTestingTimeType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesVisitWeightWomanWorkacceptability and feasibilityadult onset diabetesafter gestational diabetesclinical riskcomparative effectivenesscomplications during pregnancycostdelivered on-linedelivered onlinedesigndesigningdevelop therapydiabetesdiabetes prevention programdiabetes riskdiscountearly therapyelectronic health care recordelectronic health medical recordelectronic health plan recordelectronic health registryelectronic medical health recordempowermentenrollethnic diversityethnically diverseevidence basefacesfacialfasting plasma glucosefeasibility testingfollowing gestational diabetesgestational diabetes historyhealth assessmenthemoglobin A1chigh riskinnovateinnovationinnovativeinterestintervention developmentketosis resistant diabetesmaturity onset diabetesmotivational enhancement therapymotivational interviewmultiphase optimization strategyneglectnovelon-line deliveryonline deliveryoutreachpathwaypersonal carepost-partumpost-partum carepostpartum carepragmatic effectiveness trialpragmatic trialpregnancy carepregnancy diabetespregnancy-related complicationsprenatal appointmentprenatal checkupprenatal visitpreventpreventingprimary outcomeprogramspsychologicpsychologicalracial diversityracially diverserandomisationrandomizationrandomized trialrandomly assignedscreeningscreeningssecondary outcometheoriestherapy developmenttreatment developmenttype 2 DMtype II DMtype two diabetesuptakeweb based deliveryweights
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

ABSTRACT
Gestational diabetes mellitus (GDM) is a common complication that is routinely detected as part of standard

prenatal care. After delivery, women with GDM are 7 times more likely to develop type 2 diabetes than those

without GDM. National clinical guidelines thus urge completion of a 75-gram, 2-hour oral glucose tolerance test

(OGTT), given its superior sensitivity to detect diabetes, by 12 weeks postpartum. Clinical guidelines also

advise participation in an evidence-based lifestyle program for diabetes prevention. Yet uptake of this

recommended care remains low, and evidence from randomized trials on interventions to increase uptake

remains scarce. Here, we propose to test a novel, multi-component outreach intervention that explicitly targets

as-yet neglected, patient-level motivational and logistical barriers to engaging in preventive care during the

demanding postpartum period. We will leverage the multiphase optimization strategy (MOST) to identify, in a

randomized factorial trial, which of four theory-driven components increase actual completion of postpartum

screening and enrollment in lifestyle programs for diabetes prevention: 1) a streamlined values affirmation, 2)

personalized information about diabetes risk, 3) an interactive motivational interviewing-based module, and 4)

an interactive action planning module. Each component is designed to be self-directed and delivered securely

online via existing infrastructure in a health system setting, increasing its future potential for large-scale reach.

In a racially and ethnically diverse sample of women with GDM within the Kaiser Permanente Northern

California (KPNC) health system, our specific aims are as follows. Aim 1: Identify which of four components of

the outreach intervention increase completion of a) a 75-gram, 2-hour OGTT within 4-12 weeks postpartum,

aligned with national clinical guidelines (primary outcome), and b) any postpartum diabetes screening test

(OGTT, fasting plasma glucose, or hemoglobin A1c) by 52 weeks postpartum (secondary outcome). Aim 2:

Identify which of four components of the outreach intervention increase enrollment in a health system- or

community-based lifestyle program for diabetes prevention by 52 weeks postpartum (secondary outcome). Aim

3: Determine whether each intervention component impacts its target mediator, as predicted by its respective

theory. We will efficiently and objectively assess screening outcomes via electronic health records. Results will

yield an optimized intervention ready to be tested in a future pragmatic trial to accelerate uptake of guideline-

recommended postpartum care for women with GDM, with the long-term goal of preventing diabetes in a

diverse and high-risk clinical population.

Grant Number: 5R01DK122087-05
NIH Institute/Center: NIH

Principal Investigator: Susan Brown

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →